Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study

View Full Paper
Ask AI
Bookmark
Share

Authors

MGMahasweta GooptuSBStephanie Bo‐SubaitSSSarah Smith

Discussion

Loading...

Member takes

Overview

Phase II study reveals improved survival and lower chronic graft versus host disease in HLA-mismatched transplant recipients receiving prophylaxis.

Key Points

  • To evaluate the effectiveness of post-transplant cyclophosphamide-based prophylaxis for graft versus host disease in HLA-mismatched donor transplants.
  • Phase II study including 193 adult recipients of HLA-mismatched unrelated donor transplants
  • Participants received cyclophosphamide, tacrolimus, and mycophenolate mofetil
  • Assessment of overall survival, GVHD incidence, and severe infection rates
  • One-year overall survival estimate was 79.6%
  • Cumulative incidence rates of non-relapse mortality was 12.5% and relapse was 17.3%
  • Grade II-IV acute GVHD occurred in 40% of participants

Cite This Study

Gooptu et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df00https://doi.org/10.1182/blood-2025-4232
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Post-transplant cyclophosphamide-based graft-<i>versus-</i>host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.2024 · 5 citations
  2. 2Post-transplant cyclophosphamide based GVHD prophylaxis in HLA-matched related and unrelated donor hematopoietic cell transplantation in adults with hematologic malignancies undergoing myeloablative conditioning: A CIBMTR analysis of 8,272 participants2025
  3. 3Reduced dose post-transplant cytoxan (Intermediate -Dose) in combination with abatacept after matched unrelated donor transplant for high -risk hematological malignancy may reduce treatment related mortality and risk of relapse.2025
  4. 4Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry2025
  5. 5Outcomes after bone marrow versus peripheral blood mismatched unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based GVHD prophylaxis2025